Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
chronic hepatitis B
Biotech
GSK sees hep B therapy's efficacy drop 60% in phase 2 readout
The Big Pharma is still hopeful the antisense oligonucleotide treatment will provide a functional cure for the infection.
James Waldron
Nov 8, 2022 11:37am
GSK talks up hep B functional cure after posting phase 2 data
Jun 27, 2022 5:29am
Precision makes its case over CRISPR, touting preclinical data
May 23, 2022 3:15pm
J&J culls Bavarian Nordic pacts for HPV, hep B vax
May 9, 2022 9:47am
Aligos calls it quits on 2nd med after 'unexpected' reactions
Mar 22, 2022 10:40am
Aligos says stop right now to lead med after fruitless data
Jan 6, 2022 2:44pm
